A Worthy Finding: Decrease in Total Cholesterol and Low-Density Lipoprotein Cholesterol in Treated Mild Subclinical Hypothyroidism

被引:34
|
作者
Zhao, Meng [1 ,3 ,4 ]
Liu, Lu [1 ,3 ,4 ]
Wang, Fei [5 ]
Yuan, Zhongshang [6 ]
Zhang, Xu [1 ,3 ,4 ]
Xu, Chao [1 ,3 ,4 ]
Song, Yongfeng [1 ,3 ,4 ]
Guan, Qingbo [1 ,3 ,4 ]
Gao, Ling [2 ,3 ,4 ]
Shan, Zhongyan [7 ]
Zhang, Haiqing [1 ,3 ,4 ]
Zhao, Jiajun [1 ,3 ,4 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Endocrinol, Jinan 250021, Shandong, Peoples R China
[2] Shandong Univ, Shandong Prov Hosp, Ctr Sci, Jinan 250021, Shandong, Peoples R China
[3] Shandong Clin Med Ctr Endocrinol & Metab, Jinan, Peoples R China
[4] Shandong Acad Clin Med, Inst Endocrinol & Metab, Jinan, Peoples R China
[5] Ningxia Med Univ, Sch Clin Med, Yinchuan, Peoples R China
[6] Shandong Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Jinan 250021, Shandong, Peoples R China
[7] China Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Shenyang, Peoples R China
关键词
CORONARY-HEART-DISEASE; THYROID-STIMULATING HORMONE; INTIMA-MEDIA THICKNESS; SERUM-LIPID PROFILES; ALL-CAUSE MORTALITY; L-THYROXINE; HASHIMOTOS-THYROIDITIS; ENDOTHELIAL FUNCTION; CARDIOVASCULAR RISK; CONTROLLED-TRIAL;
D O I
10.1089/thy.2016.0010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Mild subclinical hypothyroidism (SCH) affects a large number of people and is known to be a risk factor for dyslipidemia. However, whether mild SCH patients should be treated with L-thyroxine to improve lipid profiles remains controversial. In addition, it is also unclear whether all mild SCH patients can benefit from L-thyroxine treatment, regardless of basal thyrotropin or lipid levels. This study aimed to assess the effects of L-thyroxine replacement therapy on the lipid profiles of mild SCH patients. Methods: This open-label randomized controlled trial was performed in Ningyang County, Shandong Province, China. A total of 378 mild SCH patients with diagnoses confirmed by two thyroid function tests were randomly assigned to either the intervention group (L-thyroxine replacement therapy) or the control group (no treatment). The primary outcome was a change in serum total cholesterol (TC) concentration. Results: In all, 369 participants completed the 15-month follow-up period. Reduced TC concentrations were more prominent in the intervention group than they were in the control group (-0.41mmol/L vs. -0.17 mmol/L; p = 0.012), and changes in low-density lipoprotein cholesterol levels exhibited the same trend. Subgroup analyses were performed to assess the effects of L-thyroxine in patients with different thyrotropin or TC levels. When the study population was stratified according to basal thyrotropin concentration, all patients who had received L-thyroxine showed reduced TC levels (p < 0.001). The treatment was similarly beneficial for all patients, regardless of basal TC level. Even for subjects with TC levels <5.18 mmol/L, serum TC concentrations remained unchanged in the intervention group (p = 0.936) but increased by 0.35 mmol/L in the control group (p = 0.004). Conclusions: The findings suggest that mild SCH patients could benefit from L-thyroxine treatment to improve lipid profiles, regardless of basal thyrotropin or TC concentrations.
引用
收藏
页码:1019 / 1029
页数:11
相关论文
共 50 条
  • [1] Low-density lipoprotein cholesterol in subclinical hypothyroidism
    Vierhapper, H
    Nardi, A
    Grösser, P
    Raber, W
    Gessl, A
    THYROID, 2000, 10 (11) : 981 - 984
  • [2] Fenofibrate lowers small low-density lipoprotein with no change in total low-density lipoprotein cholesterol
    Superko, HR
    Madan, S
    Tonnemacher, D
    Chronos, N
    Garrett, B
    Sheehan, D
    Raul, E
    Frohwein, S
    McGrath, K
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 316A - 316A
  • [3] A Comparison of the Effectiveness of Statins in Reducing Total Cholesterol and Low-Density Lipoprotein Cholesterol
    But, Anna
    Suvisaari, Janne
    Suvisaari, Jaana
    Niskanen, Leo
    Haukka, Jari
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 111 - 112
  • [4] Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
    Katsiki, Niki
    Vrablik, Michal
    Banach, Maciej
    Gouni-Berthold, Ioanna
    PHARMACEUTICALS, 2023, 16 (04)
  • [5] Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria
    Tozawa, M
    Iseki, K
    Iseki, C
    Oshiro, S
    Ikemiya, Y
    Takishita, S
    KIDNEY INTERNATIONAL, 2002, 62 (05) : 1743 - 1749
  • [6] Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
    Yeang, Calvin
    Karwatowska-Prokopczuk, Ewa
    Su, Fei
    Dinh, Brian
    Xia, Shuting
    Witztum, Joseph L.
    Tsimikas, Sotirios
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (11) : 1035 - 1046
  • [7] Relativism and Low-Density Lipoprotein Cholesterol
    McCarthy, Cian P.
    McEvoy, John W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (22) : 2773 - 2774
  • [8] Beyond Low-Density Lipoprotein Cholesterol
    Arsenault, Benoit J.
    Rana, Jamal S.
    Stroes, Erik S. G.
    Despres, Jean-Pierre
    Shah, Prediman K.
    Kastelein, John J. P.
    Wareham, Nicholas J.
    Boekholdt, S. Matthijs
    Khaw, Kay-Tee
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 55 (01) : 35 - 41
  • [9] Fasting during Ramadan induces a marked increase in high-density lipoprotein cholesterol and decrease in low-density lipoprotein cholesterol
    Adlouni, A
    Ghalim, N
    Benslimane, A
    Lecerf, JM
    Saile, R
    ANNALS OF NUTRITION AND METABOLISM, 1997, 41 (04) : 242 - 249
  • [10] CYCLOSPORINE, LOW-DENSITY LIPOPROTEIN, AND CHOLESTEROL
    DEGROEN, PC
    MAYO CLINIC PROCEEDINGS, 1988, 63 (10) : 1012 - 1021